International Review of Ophthalmology ›› 2022, Vol. 46 ›› Issue (3): 247-252.doi: 10.3760/ cma.j.issn.1673-5803.2022.03.010

Previous Articles     Next Articles

The treatment of herpes simplex virus necrotizing stromal keratitis

Ni Yan, Zheng Libin, Xu Yesheng, Yao Yufeng   

  1. Department of Ophthalmology, Sir RunRun Shaw Hospital, Zhejiang University School of Medicine, Key Laboratory for Corneal Diseases Research of Zhejiang Province, Hangzhou 310000, China
  • Received:2021-09-10 Online:2022-06-22 Published:2022-06-22
  • Contact: Yao Yufeng, Email: yaoyf@zju.edu.cn
  • Supported by:
    Key Research & Development Projects of Zhejiang Province (2018C03082); National Natural Science Foundation of China (U20A20387); Health Commission of Zhejiang Province (WKJ-ZJ-1905); Health Commission of Zhejiang Province (2019ZD040)

Abstract: Herpes simplex virus necrotizing stromal keratitis (HSV NSK) is a kind of rare eye disease mainly characterized by stromal necrosis, which can lead to vision loss, corneal perforation, even blindness and enucleation. At present, the management of HSV NSK can be divided into non-surgical procedure and surgical treatment. Non-surgical procedure includes antiviral drugs such as nucleoside analogues, IFN-γ-ASON, DMF, CsA, vaccine, etc. In the event of serious cases beyond the control of non-surgical therapy, surgical management is necessary. Common clinical surgeries include penetrating keratoplasty (PKP), deep anterior lamellar keratoplasty (DALK), multilayer amniotic membrane transplantation (AMT), and conjunctival flap coverage and so on. (Int Rev Ophthalmol, 2022, 46: 247-252)

Key words: herpes simplex virus, necrotizing stromal keratitis, inflammatory response, keratoplasty